INDIVIDUALIZED ANTI-TUMOR VACCINES Russian patent published in 2022 - IPC A61K39/00 A61P35/00 C12Q1/68 C07K14/47 

FIELD: pharmaceutics; medicine.

SUBSTANCE: object 1 is a method for the production of an individualized vaccine for use in the treatment or prevention of cancer, including the effective amount of recombinant polyepitope polypeptide containing mutation-based neoepitopes, which are the result of cancer-specific somatic mutations in a cancer sample of a patient with cancer, or nucleic acid encoding the specified polyepitope polypeptide, where mutation-based neoepitopes are cross-linked together by means of peptide bonds or linkers. The method includes stages of identification of cancer-specific somatic mutations in the cancer sample of the patient with cancer to obtain a signature of patient’s cancer mutations and to obtain a vaccine, a characteristic feature of which is the obtained cancer mutation signature. Objects 2 and 3 are an individualized vaccine for use in the treatment or prevention of cancer. Object 4 is a method for the treatment of a patient with cancer, including the administration of a vaccine to the patient.

EFFECT: creation of an individualized antitumor vaccine due to obtaining an active vaccine start based on cancer-specific somatic mutations in a cancer sample of a patient with cancer.

30 cl, 21 dwg, 8 tbl, 9 ex